Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 1/20 | 0.63 |
| ▸ | HTR1B | P28222 | 1/20 | 0.63 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | THPO | P40225 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6996942 | 0.85 | SLC6A4 (0.61) | HTR1DHTR1BSLC6A4CYP1A2CYP3A4 | |
| SCHEMBL7011235 | 0.85 | SLC6A4 (0.84) | HTR1BSLC6A4OPRM1OPRK1OPRL1 | |
| SCHEMBL8381443 | 0.85 | CYP1A2 (0.63) | HTR1DHTR1BSLC6A4CYP1A2CYP3A4 | |
| SCHEMBL6995996 | 0.83 | SLC6A4 (0.59) | HTR1DHTR1BSLC6A4CYP1A2CYP3A4 | |
| SCHEMBL7014117 | 0.82 | SLC6A4 (0.56) | HTR1DHTR1BSLC6A4CYP1A2CYP3A4 | |
| SCHEMBL7014120 | 0.82 | SLC6A4 (0.56) | HTR1DHTR1BSLC6A4CYP1A2CYP3A4 | |
| SCHEMBL6997701 | 0.82 | HTR1D (0.57) | HTR1DHTR1BSLC6A4CYP1A2CYP3A4 | |
| SCHEMBL7002497 | 0.82 | SLC6A4 (0.61) | HTR1DHTR1BSLC6A4CYP1A2CYP3A4 | |
| SCHEMBL8713966 | 0.80 | HTR1D (0.55) | HTR1DHTR1BSLC6A4 | |
| SCHEMBL8708637 | 0.80 | HTR1D (0.42) | HTR1DHTR1BSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125645-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | VALORISATION HSJ LP (CA) | 2026-05-07 | — | — | US | disclosed |
| WO-2024073845-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | VALORISATION HSJ, LIMITED PARTNERSHIP (CA) | 2024-04-11 | — | — | WO | disclosed |
| EP-0978514-B1 | Indazole derivatives as 5-HT1F agonists | LILLY CO ELI (US) | 2004-12-15 | — | — | EP | disclosed |
| EP-1089993-B1 | 5-HT1F AGONISTS | LILLY CO ELI (US) | 2003-10-22 | — | — | EP | disclosed |
| US-6358972-B1 | FOR THERAPY OF MIGRAINE | ELI LILLY AND COMPANY | 2002-03-19 | — | — | US | disclosed |
| EP-1089993-A1 | 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 2001-04-11 | — | — | EP | disclosed |
| US-6133290-A | 5-HT1F agonists | ELI LILLY AND COMPANY (US) | 2000-10-17 | — | — | US | disclosed |
| WO-2000006173-A1 | 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 2000-02-10 | — | — | WO | disclosed |
| EP-0978514-A1 | Indazole derivatives as 5-HT1F agonists | ELI LILLY AND COMPANY (US) | 2000-02-09 | — | — | EP | disclosed |
| WO-2000000487-A1 | 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 2000-01-06 | — | — | WO | disclosed |
| WO-2000000490-A2 | 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 2000-01-06 | — | — | WO | disclosed |
| US-5874427-A | MIGRAINE | ELI LILLY AND COMPANY (US) | 1999-02-23 | — | — | US | disclosed |
| EP-0875513-A1 | Substituted heteroaromatic 5-HT 1F agonists | ELI LILLY AND COMPANY (US) | 1998-11-04 | — | — | EP | disclosed |
| WO-1998046570-A1 | SUBSTITUTED HETEROAROMATIC 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 1998-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125645-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | HTR1F, HTR1A, HTR1D | HTR1D 3/4885HTR1B 4/4885SLC6A4 299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.